← 產業報告目錄

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-02-14頁數 215報告編號 MRFRLS0821HCR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032 Market Overview The biosimilars market is predicted to expand from 11.39 (USD Billion) in 2023 to 41.6 (USD Billion) by 2032. The Biosimilars Market CAGR (growth rate) is anticipated to be approximately 15.49% over the forecast period. Several main drivers are driving the biosimilars industry, including an increase in the prevalence of chronic diseases and a growing need for inexpensive biologic treatments. As healthcare costs continue to grow, biosimilars provide a cost-effective alternative that can improve patient access to critical therapies. Regulatory reforms and developments in manufacturing processes also contribute to market growth by streamlining the approval process and improving product quality. The transition to value-based care models stresses the necessity of low-cost treatment choices, making biosimilars a crucial component of the healthcare ecosystem. Market segment insights The Biosimilars Market is expanding rapidly, notably in the Type category, which includes key medicinal goods such as monoclonal antibodies, insulin, erythropoietin, and growth hormones. The Biosimilars Market is growing rapidly, with a valuation of 11.39 USD billion in 2023 and a forecast revenue of 41.6 USD billion by 2032. This expansion can be attributable to rising demand for more cost-effective treatment alternatives across a variety of therapeutic areas, particularly in the Application segment. In the Biosimilars Market, the End Use segment is critical to establishing the landscape of healthcare delivery. By 2023, the total market is predicted to be worth 11.39 billion USD, indicating the industry's strong expansion. Hospitals are a prominent player in this area, as they increasingly use biosimilars to reduce treatment costs and improve patient outcomes. Clinics also make a substantial contribution, catering to a vast patient population seeking cost-effective solutions in a variety of therapeutic fields. The Biosimilars sector was assessed at 11.39 USD billion in 2023, with strong growth projected in the following years as the sector transitions to advanced manufacturing technologies. Within the Manufacturing Process category, technologies such as Recombinant DNA Technology and Hybridoma Technology play critical roles in biosimilar development. Regional insights The Biosimilars Market is expected to grow rapidly across all regions, with North America, Europe, APAC, South America, and MEA contributing significantly to revenue. North America maintains a majority stake worth 5.0 USD billion in 2023 and is expected to grow to 17.5 USD billion by 2032, proving its dominance in the business due to a robust healthcare infrastructure and increased demand for cost-effective therapies. Europe follows closely, with a valuation of 3.5 USD billion in 2023 and a projected growth rate of 13.0 USD billion, owing to favorable regulations and increased acceptance of biosimilars among healthcare professionals. The APAC region is rising, with a value of 2.0 USD billion in 2023 and an expected growth to 8.0 USD billion, demonstrating promise due to growing patient populations and increased healthcare investments. South America and MEA are smaller markets, with valuations of 0.7 USD billion and 0.19 USD billion respectively in 2023, but they offer chances for growth as healthcare systems expand and access to biosimilars improves. The overall Biosimilars Market data reflects a dynamic growth landscape influenced by regional healthcare policies, patient access to medications, and the economic benefits associated with biosimilar therapies. Key players Key Companies in the Biosimilars Market Include Zydus Cadila, Eli Lilly, Samsung Bioepis, GSK, AbbVie, Boehringer Ingelheim, Teva Pharmaceutical Industries, Celltrion, Fresenius Kabi, Amgen, Reddy's Laboratories, Mylan, Sandoz, Pfizer, and Novartis.
目錄 Table of Contents
TABLE OF CONTENTS 1. EXECUTIVE SUMMARY 1.1. MARKET OVERVIEW 1.2. KEY FINDINGS 1.3. MARKET SEGMENTATION 1.4. COMPETITIVE LANDSCAPE 1.5. CHALLENGES AND OPPORTUNITIES 1.6. FUTURE OUTLOOK 2. MARKET INTRODUCTION 2.1. DEFINITION 2.2. SCOPE OF THE STUDY 2.2.1. RESEARCH OBJECTIVE 2.2.2. ASSUMPTION 2.2.3. LIMITATIONS 3. RESEARCH METHODOLOGY 3.1. OVERVIEW 3.2. DATA MINING 3.3. SECONDARY RESEARCH 3.4. PRIMARY RESEARCH 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS 3.5. FORECASTING MODEL 3.6. MARKET SIZE ESTIMATION 3.6.1. BOTTOM-UP APPROACH 3.6.2. TOP-DOWN APPROACH 3.7. DATA TRIANGULATION 3.8. VALIDATION 4. MARKET DYNAMICS 4.1. OVERVIEW 4.2. DRIVERS 4.3. RESTRAINTS 4.4. OPPORTUNITIES 5. MARKET FACTOR ANALYSIS 5.1. VALUE CHAIN ANALYSIS 5.2. PORTER'S FIVE FORCES ANALYSIS 5.2.1. BARGAINING POWER OF SUPPLIERS 5.2.2. BARGAINING POWER OF BUYERS 5.2.3. THREAT OF NEW ENTRANTS 5.2.4. THREAT OF SUBSTITUTES 5.2.5. INTENSITY OF RIVALRY 5.3. COVID-19 IMPACT ANALYSIS 5.3.1. MARKET IMPACT ANALYSIS 5.3.2. REGIONAL IMPACT 5.3.3. OPPORTUNITY AND THREAT ANALYSIS 6. BIOSIMILARS MARKET, BY TYPE (USD BILLION) 6.1. MONOCLONAL ANTIBODIES 6.2. INSULIN 6.3. ERYTHROPOIETIN 6.4. GROWTH HORMONES 7. BIOSIMILARS MARKET, BY APPLICATION (USD BILLION) 7.1. ONCOLOGY 7.2. DIABETES 7.3. AUTOIMMUNE DISEASES 7.4. CHRONIC INFLAMMATORY DISEASES 8. BIOSIMILARS MARKET, BY END USE (USD BILLION) 8.1. HOSPITALS 8.2. CLINICS 8.3. HOMECARE 8.4. RESEARCH INSTITUTIONS 9. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS (USD BILLION) 9.1. RECOMBINANT DNA TECHNOLOGY 9.2. HYBRIDOMA TECHNOLOGY 9.3. TRANSGENIC TECHNOLOGY 10. BIOSIMILARS MARKET, BY REGIONAL (USD BILLION) 10.1. NORTH AMERICA 10.1.1. US 10.1.2. CANADA 10.2. EUROPE 10.2.1. GERMANY 10.2.2. UK 10.2.3. FRANCE 10.2.4. RUSSIA 10.2.5. ITALY 10.2.6. SPAIN 10.2.7. REST OF EUROPE 10.3. APAC 10.3.1. CHINA 10.3.2. INDIA 10.3.3. JAPAN 10.3.4. SOUTH KOREA 10.3.5. MALAYSIA 10.3.6. THAILAND 10.3.7. INDONESIA 10.3.8. REST OF APAC 10.4. SOUTH AMERICA 10.4.1. BRAZIL 10.4.2. MEXICO 10.4.3. ARGENTINA 10.4.4. REST OF SOUTH AMERICA 10.5. MEA 10.5.1. GCC COUNTRIES 10.5.2. SOUTH AFRICA 10.5.3. REST OF MEA 11. COMPETITIVE LANDSCAPE 11.1. OVERVIEW 11.2. COMPETITIVE ANALYSIS 11.3. MARKET SHARE ANALYSIS 11.4. MAJOR GROWTH STRATEGY IN THE BIOSIMILARS MARKET 11.5. COMPETITIVE BENCHMARKING 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOSIMILARS MARKET 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT 11.7.2. MERGER & ACQUISITIONS 11.7.3. JOINT VENTURES 11.8. MAJOR PLAYERS FINANCIAL MATRIX 11.8.1. SALES AND OPERATING INCOME 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023 12. COMPANY PROFILES 12.1. ZYDUS CADILA 12.1.1. FINANCIAL OVERVIEW 12.1.2. PRODUCTS OFFERED 12.1.3. KEY DEVELOPMENTS 12.1.4. SWOT ANALYSIS 12.1.5. KEY STRATEGIES 12.2. ELI LILLY 12.2.1. FINANCIAL OVERVIEW 12.2.2. PRODUCTS OFFERED 12.2.3. KEY DEVELOPMENTS 12.2.4. SWOT ANALYSIS 12.2.5. KEY STRATEGIES 12.3. SAMSUNG BIOEPIS 12.3.1. FINANCIAL OVERVIEW 12.3.2. PRODUCTS OFFERED 12.3.3. KEY DEVELOPMENTS 12.3.4. SWOT ANALYSIS 12.3.5. KEY STRATEGIES 12.4. GSK 12.4.1. FINANCIAL OVERVIEW 12.4.2. PRODUCTS OFFERED 12.4.3. KEY DEVELOPMENTS 12.4.4. SWOT ANALYSIS 12.4.5. KEY STRATEGIES 12.5. ABBVIE 12.5.1. FINANCIAL OVERVIEW 12.5.2. PRODUCTS OFFERED 12.5.3. KEY DEVELOPMENTS 12.5.4. SWOT ANALYSIS 12.5.5. KEY STRATEGIES 12.6. BOEHRINGER INGELHEIM 12.6.1. FINANCIAL OVERVIEW 12.6.2. PRODUCTS OFFERED 12.6.3. KEY DEVELOPMENTS 12.6.4. SWOT ANALYSIS 12.6.5. KEY STRATEGIES 12.7. TEVA PHARMACEUTICAL INDUSTRIES 12.7.1. FINANCIAL OVERVIEW 12.7.2. PRODUCTS OFFERED 12.7.3. KEY DEVELOPMENTS 12.7.4. SWOT ANALYSIS 12.7.5. KEY STRATEGIES 12.8. CELLTRION 12.8.1. FINANCIAL OVERVIEW 12.8.2. PRODUCTS OFFERED 12.8.3. KEY DEVELOPMENTS 12.8.4. SWOT ANALYSIS 12.8.5. KEY STRATEGIES 12.9. FRESENIUS KABI 12.9.1. FINANCIAL OVERVIEW 12.9.2. PRODUCTS OFFERED 12.9.3. KEY DEVELOPMENTS 12.9.4. SWOT ANALYSIS 12.9.5. KEY STRATEGIES 12.10. AMGEN 12.10.1. FINANCIAL OVERVIEW 12.10.2. PRODUCTS OFFERED 12.10.3. KEY DEVELOPMENTS 12.10.4. SWOT ANALYSIS 12.10.5. KEY STRATEGIES 12.11. REDDY'S LABORATORIES 12.11.1. FINANCIAL OVERVIEW 12.11.2. PRODUCTS OFFERED 12.11.3. KEY DEVELOPMENTS 12.11.4. SWOT ANALYSIS 12.11.5. KEY STRATEGIES 12.12. MYLAN 12.12.1. FINANCIAL OVERVIEW 12.12.2. PRODUCTS OFFERED 12.12.3. KEY DEVELOPMENTS 12.12.4. SWOT ANALYSIS 12.12.5. KEY STRATEGIES 12.13. SANDOZ 12.13.1. FINANCIAL OVERVIEW 12.13.2. PRODUCTS OFFERED 12.13.3. KEY DEVELOPMENTS 12.13.4. SWOT ANALYSIS 12.13.5. KEY STRATEGIES 12.14. PFIZER 12.14.1. FINANCIAL OVERVIEW 12.14.2. PRODUCTS OFFERED 12.14.3. KEY DEVELOPMENTS 12.14.4. SWOT ANALYSIS 12.14.5. KEY STRATEGIES 12.15. NOVARTIS 12.15.1. FINANCIAL OVERVIEW 12.15.2. PRODUCTS OFFERED 12.15.3. KEY DEVELOPMENTS 12.15.4. SWOT ANALYSIS 12.15.5. KEY STRATEGIES 13. APPENDIX 13.1. REFERENCES 13.2. RELATED REPORTS
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1. LIST OF ASSUMPTIONS TABLE 2. NORTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 3. NORTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 4. NORTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 5. NORTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 6. NORTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 7. US BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 8. US BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 9. US BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 10. US BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 11. US BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 12. CANADA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 13. CANADA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 14. CANADA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 15. CANADA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 16. CANADA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 17. EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 18. EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 19. EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 20. EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 21. EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 22. GERMANY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 23. GERMANY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 24. GERMANY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 25. GERMANY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 26. GERMANY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 27. UK BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 28. UK BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 29. UK BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 30. UK BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 31. UK BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 32. FRANCE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 33. FRANCE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 34. FRANCE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 35. FRANCE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 36. FRANCE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 37. RUSSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 38. RUSSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 39. RUSSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 40. RUSSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 41. RUSSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 42. ITALY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 43. ITALY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 44. ITALY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 45. ITALY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 46. ITALY BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 47. SPAIN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 48. SPAIN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 49. SPAIN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 50. SPAIN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 51. SPAIN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 52. REST OF EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 53. REST OF EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 54. REST OF EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 55. REST OF EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 56. REST OF EUROPE BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 57. APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 58. APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 59. APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 60. APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 61. APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 62. CHINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 63. CHINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 64. CHINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 65. CHINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 66. CHINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 67. INDIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 68. INDIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 69. INDIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 70. INDIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 71. INDIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 72. JAPAN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 73. JAPAN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 74. JAPAN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 75. JAPAN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 76. JAPAN BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 77. SOUTH KOREA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 78. SOUTH KOREA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 79. SOUTH KOREA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 80. SOUTH KOREA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 81. SOUTH KOREA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 82. MALAYSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 83. MALAYSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 84. MALAYSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 85. MALAYSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 86. MALAYSIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 87. THAILAND BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 88. THAILAND BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 89. THAILAND BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 90. THAILAND BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 91. THAILAND BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 92. INDONESIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 93. INDONESIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 94. INDONESIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 95. INDONESIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 96. INDONESIA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 97. REST OF APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 98. REST OF APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 99. REST OF APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 100. REST OF APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 101. REST OF APAC BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 102. SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 103. SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 104. SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 105. SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 106. SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 107. BRAZIL BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 108. BRAZIL BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 109. BRAZIL BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 110. BRAZIL BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 111. BRAZIL BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 112. MEXICO BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 113. MEXICO BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 114. MEXICO BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 115. MEXICO BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 116. MEXICO BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 117. ARGENTINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 118. ARGENTINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 119. ARGENTINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 120. ARGENTINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 121. ARGENTINA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 122. REST OF SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 123. REST OF SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 124. REST OF SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 125. REST OF SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 126. REST OF SOUTH AMERICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 127. MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 128. MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 129. MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 130. MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 131. MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 132. GCC COUNTRIES BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 133. GCC COUNTRIES BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 134. GCC COUNTRIES BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 135. GCC COUNTRIES BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 136. GCC COUNTRIES BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 137. SOUTH AFRICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 138. SOUTH AFRICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 139. SOUTH AFRICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 140. SOUTH AFRICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 141. SOUTH AFRICA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 142. REST OF MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD BILLIONS) TABLE 143. REST OF MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) TABLE 144. REST OF MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2032 (USD BILLIONS) TABLE 145. REST OF MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY MANUFACTURING PROCESS, 2019-2032 (USD BILLIONS) TABLE 146. REST OF MEA BIOSIMILARS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL TABLE 148. ACQUISITION/PARTNERSHIP LIST OF FIGURES FIGURE 1. MARKET SYNOPSIS FIGURE 2. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS FIGURE 3. US BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 4. US BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 5. US BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 6. US BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 7. US BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 8. CANADA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 9. CANADA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 10. CANADA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 11. CANADA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 12. CANADA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 13. EUROPE BIOSIMILARS MARKET ANALYSIS FIGURE 14. GERMANY BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 15. GERMANY BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 16. GERMANY BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 17. GERMANY BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 18. GERMANY BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 19. UK BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 20. UK BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 21. UK BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 22. UK BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 23. UK BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 24. FRANCE BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 25. FRANCE BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 26. FRANCE BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 27. FRANCE BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 28. FRANCE BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 29. RUSSIA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 30. RUSSIA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 31. RUSSIA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 32. RUSSIA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 33. RUSSIA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 34. ITALY BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 35. ITALY BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 36. ITALY BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 37. ITALY BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 38. ITALY BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 39. SPAIN BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 40. SPAIN BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 41. SPAIN BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 42. SPAIN BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 43. SPAIN BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 44. REST OF EUROPE BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 45. REST OF EUROPE BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 46. REST OF EUROPE BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 47. REST OF EUROPE BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 48. REST OF EUROPE BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 49. APAC BIOSIMILARS MARKET ANALYSIS FIGURE 50. CHINA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 51. CHINA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 52. CHINA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 53. CHINA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 54. CHINA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 55. INDIA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 56. INDIA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 57. INDIA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 58. INDIA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 59. INDIA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 60. JAPAN BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 61. JAPAN BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 62. JAPAN BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 63. JAPAN BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 64. JAPAN BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 65. SOUTH KOREA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 66. SOUTH KOREA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 67. SOUTH KOREA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 68. SOUTH KOREA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 69. SOUTH KOREA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 70. MALAYSIA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 71. MALAYSIA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 72. MALAYSIA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 73. MALAYSIA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 74. MALAYSIA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 75. THAILAND BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 76. THAILAND BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 77. THAILAND BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 78. THAILAND BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 79. THAILAND BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 80. INDONESIA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 81. INDONESIA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 82. INDONESIA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 83. INDONESIA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 84. INDONESIA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 85. REST OF APAC BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 86. REST OF APAC BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 87. REST OF APAC BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 88. REST OF APAC BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 89. REST OF APAC BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 90. SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS FIGURE 91. BRAZIL BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 92. BRAZIL BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 93. BRAZIL BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 94. BRAZIL BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 95. BRAZIL BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 96. MEXICO BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 97. MEXICO BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 98. MEXICO BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 99. MEXICO BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 100. MEXICO BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 101. ARGENTINA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 102. ARGENTINA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 103. ARGENTINA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 104. ARGENTINA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 105. ARGENTINA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 106. REST OF SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 107. REST OF SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 108. REST OF SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 109. REST OF SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 110. REST OF SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 111. MEA BIOSIMILARS MARKET ANALYSIS FIGURE 112. GCC COUNTRIES BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 113. GCC COUNTRIES BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 114. GCC COUNTRIES BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 115. GCC COUNTRIES BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 116. GCC COUNTRIES BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 117. SOUTH AFRICA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 118. SOUTH AFRICA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 119. SOUTH AFRICA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 120. SOUTH AFRICA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 121. SOUTH AFRICA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 122. REST OF MEA BIOSIMILARS MARKET ANALYSIS BY TYPE FIGURE 123. REST OF MEA BIOSIMILARS MARKET ANALYSIS BY APPLICATION FIGURE 124. REST OF MEA BIOSIMILARS MARKET ANALYSIS BY END USE FIGURE 125. REST OF MEA BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING PROCESS FIGURE 126. REST OF MEA BIOSIMILARS MARKET ANALYSIS BY REGIONAL FIGURE 127. KEY BUYING CRITERIA OF BIOSIMILARS MARKET FIGURE 128. RESEARCH PROCESS OF MRFR FIGURE 129. DRO ANALYSIS OF BIOSIMILARS MARKET FIGURE 130. DRIVERS IMPACT ANALYSIS: BIOSIMILARS MARKET FIGURE 131. RESTRAINTS IMPACT ANALYSIS: BIOSIMILARS MARKET FIGURE 132. SUPPLY / VALUE CHAIN: BIOSIMILARS MARKET FIGURE 133. BIOSIMILARS MARKET, BY TYPE, 2024 (% SHARE) FIGURE 134. BIOSIMILARS MARKET, BY TYPE, 2019 TO 2032 (USD Billions) FIGURE 135. BIOSIMILARS MARKET, BY APPLICATION, 2024 (% SHARE) FIGURE 136. BIOSIMILARS MARKET, BY APPLICATION, 2019 TO 2032 (USD Billions) FIGURE 137. BIOSIMILARS MARKET, BY END USE, 2024 (% SHARE) FIGURE 138. BIOSIMILARS MARKET, BY END USE, 2019 TO 2032 (USD Billions) FIGURE 139. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS, 2024 (% SHARE) FIGURE 140. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS, 2019 TO 2032 (USD Billions) FIGURE 141. BIOSIMILARS MARKET, BY REGIONAL, 2024 (% SHARE) FIGURE 142. BIOSIMILARS MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions) FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS

提及公司

Zydus CadilaEli LillySamsung BioepisGSKAbbVieBoehringer IngelheimTeva Pharmaceutical IndustriesCelltrionFresenius KabiAmgenReddy's LaboratoriesMylanSandozPfizerand Novartis

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們